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ABSTRACT: Acid-sensing ion channels (ASICs) are a family of ion channels permeable to cations and largely responsible for the 
onset of acid-evoked ion currents both in neurons and in different types of cancer cells, thus representing a potential target for drug 
discovery. Owing to the limited attention ASIC2 has received so far, an exploratory programme was initiated to identify ASIC2 
inhibitors using Diminazene, a known pan-ASIC inhibitor, as a chemical starting point for structural elaboration. The performed 
exploration enabled the identification of a novel series of ASIC2 inhibitors. In particular, compound 2u is a brain penetrant ASIC2 
inhibitor endowed with an optimal pharmacokinetic profile. This compound may represent a useful tool to validate in animal models in vivo 
the role of ASIC2 in different neurodegenerative central nervous system pathologies.
The variation of proton concentration in tissues is a tightly 
controlled process.1 In particular, a decrease of pH has been 
observed both in physiological conditions, i.e. control of neuronal 
functions by proton-mediated signalling, and pathological 
conditions.2,3 Notably, acidification occurring in pathological 
conditions was found to recruit acid-sensing ion channels (ASICs), 
a family of proton-activated ion channels4 that are highly expressed 
both in central and peripheral neurons5 and in different types of 
cancer cells,6 thus representing a potential target for drug 
discovery.3,7 ASICs are voltage-insensitive ion channels belonging 
to the ENaC/DEG channel super-family, which includes epithelial 
Na+ channels (ENaC) and degenerins (DEG). Four ASICs genes 
(ASIC1-4) and two specific splice variants for ASIC1 and ASIC2 
(a and b) have been described in mammals to date. ASIC1a, 
ASIC2a, and ASIC2b are primarily expressed in central nervous 
system (CNS) neurons, while all subunits are expressed in the 
peripheral nervous system (PNS). ASIC1a, ASIC 2a and ASIC3 
subunits assemble to form both homotrimeric and heterotrimeric 
channels, whereas ASIC2b and ASIC4 only contribute to forming 
heteromeric channels with other ASIC subunits.7,8 In terms of 
electrophysiology, while ASIC1a undergoes rapid inactivation, for 
ASIC2 and ASIC3 a non-inactivated current was observed, 
potentially relevant in chronic pathologies. Thus far, both ASIC1 
and ASIC3 have been extensively studied,9 while ASIC2 has 
received much less attention. Notably, ASIC2 have recently been 
proposed as relevant target in some forms of cancer10,11 whereas, in 
combination with ASIC1 subunits, appear to play a key role in 
neuronal physiopathology.12 Several natural peptides and synthetic 
small molecules, i.e. diminazene 1 (DA, Chart 1), an anti-infective 
veterinary drug, have been described as ASICs inhibitor.13,14,15 
However, the latter compound shows both poor target and ASIC 
isoform specificity, along with negligible blood-brain barrier 
(BBB) penetration, hence limiting its  usage as therapeutic agent 
both for CNS and PNS pathologies.16,17 Hence, an exploratory 
projects was initiated, using DA as chemical starting point, to 
obtain brain penetrant ASIC2 inhibitors as useful tool compounds 
for target validation studies in CNS. To this aim, being ASIC1a and 
ASIC2a the most highly expressed ASIC subunits in CNS neurons, 
the new chemical entities (NCEs) synthesized were specifically 
tested for their effects on murine homotrimeric ASIC1a and 
ASIC2a and on the heterotrimeric ASIC1a/2a.18 
Chart 1. Structure of diminazene (DA) 1 and early lead 2a 
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To identify the most appropriate methodology for in vitro screening 
of NCEs, a series of published data19,20,21 on both compound 1 and 
Amiloride, a diuretic drug known to interact with ASICs, 
specifically drawn our attention and an optical technology based on 
membrane potential detection by voltage-sensitive dyes (VSDs) 
22,23,24,25 was proposed. This original assay format showed an 
adequate throughput performance and ability to efficiently predict 
the inhibitory effect of ASICs inhibitors. Moreover, additional 
evidence suggested the use of optic based assays, owing to the 
membrane potential sensitivity of ASIC1a binding affinity to small 
molecules.20
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The preliminary structural elaboration of DA, in three sequential 
steps, enabled the identification, of the 1,4-diaryl, 3-5-
dimethylpyrazole derivative 2a (Chart 1), an early lead compound 
which was fully characterized in terms of ASICs inhibition. In 
particular, the linear triazene linker present in DA was initially 
replaced by a 1,3-disubstituted 5-membered heterocycle, with the 
aim to rigidify the molecular core. Then, to reduce the basic 
character of the molecule, with the aim to improve drug-like 
character and possibly secure BBB permeability, one of the two 
amidine functions was successfully removed, Finally, an initial 
exploration was made on the effect of the substitution of the 
terminal phenyl ring. 
As shown in Table 1, compound 2a exhibited greater in vitro 
activity than compound 1 and comparable activity on ASIC2a and 
ASIC1a/2a (IC50 = 18.9 M and 10.9 M, respectively), while 
being inactive on ASIC1a. Based on these preliminary encouraging 
results, the rapid “4 points” analoging exploration strategy, as 
depicted in Chart 2, focused on the sequential elaboration of the 
two aryl moieties (“pink and green”), the heterocycle core 
(“fuchsia”) and the suitable rigidification/masking of the 
potentially metabolically labile terminal benzyl function (“cyan”), 
was envisioned.
Chart 2. Structural optimization of early lead 2a 
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F
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Scheme 1. Variations on the 4-aryl substituent: compounds 2a-
ia 
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2a R1=F, R2=H, X=CH
2b R1=Cl, R2=H, X=CH
2c R1=CH3, R2=H, X=CH
2d R1=OCH3, R2=H, X=CH
2e R1=CF3, R2=H, X=CH
2f R1=CH2NH2, R2=H, X=CH
2g R1=H, R2=F, X=CH
2h R1=CH3, R2=F, X=CH
2i R1=CH3, R2=H, X=N
R1
R2
R1
R2
aReagents and conditions: (a) di-tert-butyl diazene 1,2-
dicarboxylate, Cu(OAc)2.H2O, MeOH, 65°C, 1h; (b) pentane-2,4-
dione, 4N HCl in dioxane, r.t., 10 min then 80°C, 10 min, 76% (two 
steps); (c) NBS, EtOAc, sonication, 25-30°C, 15 min, 80%; (d) 
substituted aryl/pyridinyl boronic acid, Pd(PPh3)4, aq. Na2CO3, 
DMF, microwave reactor, 140°C, 15-20 min, 52%-70%; (e) 
LiAlH4, THF, r.t, 0.5-3 h, 18-75%. 
At first, following the synthetic strategy shown in Scheme 1 nine 
“pink” analogues 2a-i were synthesized. In particular, p-
cyanophenyl boronic acid 3 was reacted with di-tert-butyl diazene 
1,2-dicarboxylate and 2,4-pentanedione, to obtain the 3,5-dimethyl 
pyrazole 4. The following bromination reaction with NBS led to 
the 4-bromo analogue 5, which was coupled with 9 different aryl 
or heteroaryl substituted boronic acids. The resulting 1-(p-
cyanophenyl) pyrazoles 6a-i were reduced to the corresponding 
benzylamines 2a-i with lithium aluminium hydride in moderate to 
good overall yields.
The inhibition of ASICs constructs by compounds 2a-i is reported 
in Table 1.
Table 1. Compounds 2a-i: ASICs inhibitiona
Entry ASIC1a a ASIC2a a ASIC1a/2a a
1 (DA) 56.9 ± 8.9 169.0 ± 18.1 45.2 ± 8.8
2a >30 18.9 ± 6.9 10.9 ± 1.6
2b >30 >30 >30
2c >30 8.8 ± 2.0 >30
2d >30 16.3 ± 4.6 >30
2e >30b >30b >30
2f >30 >30 >30
2g >30 4.3 ± 0.5 >30
2h >30 >30 >30
2i >30 >30 >30
a IC50 were determined as described in the Supplementary 
Information; they are expressed in M and are the average value of 
at least n=3 independent experiments ± SEM. 
As shown in Table 1, monosubstituted compounds 2c and 2d, 
bearing a p-CH3 or p-OCH3 respectively, mostly retained the 
activity of the pyrazole lead compound 2a, while isoform-
selectivity for ASIC2a vs ASIC1a/2a was improved. Compound 2g, 
the m-F analogue of 2a, was the most potent and selective 
compound of this series. Notably, larger and/or charged functions 
(2e, p-CF3; 2f, p-CH2NH2), disubstituted aryls (2h, p-CH3, m-F) 
and the presence of a pyridine as phenyl replacement (2i, p-CH3, 
X=N) led to inactive compounds. 
Then, the influence of the 3,5-dimethyl substituents present on the 
pyrazole core was evaluated by synthesizing the corresponding 
“fuchsia” des-methyl analogue 2j (Scheme 2).
Scheme 2. Scaffold hopping: des-methyl compound 2ja
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F
F
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F
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aReagents and conditions: (a) di-tert-butyl diazene-1,2-
dicarboxylate, Cu(OAc)2.H2O, MeOH, 65°C , 1h; (b) 2-(4-
fluorophenyl)propanedial, 4N HCl in dioxane, r.t., 10 min then 
80°C, 10 min, 56% two steps; (c) LiAlH4, THF, r.t, 1h, 73%. 
To this aim, p-cyanophenyl boronic acid 3 was sequentially treated 
with di-tert-butyl diazene-1,2-dicarboxylate in presence of 
Cu(OAc)2.H2O in MeOH at 65°C for 1h, followed by 2-(4-
fluorophenyl)propanedial in 4N HCl in dioxane initially at  room 
temperature for 10 min, then at 80°C for additional 10 min to give 
intermediate 7 in 56% yield. Then, reduction of the cyano group 
led to the corresponding benzylamine 2j with lithium aluminium 
hydride in 73% yield. 
Compound 2j was found inactive in terms of ASICs inhibition (IC50 
> 30 M on all ASICs constructs, Table 2), pointing out the 
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relevance of both methyl groups for the recognition of the receptor 
binding site.
To acquire additional SAR information, a methylene spacer was 
introduced between the N1 of the pyrazole moiety (“fuchsia” 
compound 2k, Scheme 3) by bromination and Suzuki coupling on 
3,5-dimethyl pyrazole 8, followed by alkylation at the N1 position 
of 3,5-dimethyl pyrazole derivative 10a with p-CN benzyl 
bromide, and by final reduction of the nitrile group with lithium 
aluminium hydride in poor, unoptimized yields.
Scheme 3. Spacer introduction: compound 2ka
11a2k
N
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N
N
F
CN
HN
N
F
HN
N
Br
HN
N
10a
a b
c
d
8 9
aReagents and conditions: (a) NBS, EtOAc, sonication, 25-30°C, 
15 min, quantitative; (b) 4-(fluorophenyl)boronic acid or 3-
(fluorophenyl)boronic acid, Pd(PPh3)4, sat. Na2CO3, DMF, 140°C, 
20 min, 70%; (c) 4-(bromomethyl)benzonitrile, Cs2CO3, CH3CN, 
50°C, 10h, quantitative; (d) LiAlH4, THF, r.t, 1h, 9%. 
When compound 2k was tested for its ability to inhibit ASICs a 
comparable activity and isoform-selectivity was observed for 
ASIC2a with respect to compound 2a (Table 2, IC50 = 16.8 M and 
18.9 M, respectively). 
Our attention was then focused on the “blue” exploration by 
initially moving the p-benzylamine moiety from para to meta 
position of the phenyl ring (compound 2l, Scheme 4), by 
introducing a methyl group at the benzylic position (compound 2m, 
Scheme 4), and by C-1 homologation (compound 2n, Scheme 4).
In particular, as for the synthesis of 2l, 4-(p-fluorophenyl)-3,5-
dimethyl pyrazole 10a was N-arylated with m-cyanophenyl 
boronic acid using copper(II) acetate; the resulting 1-(m-
cyanophenyl) pyrazole 12 was reduced to the corresponding 
benzylamine 2l with lithium aluminium hydride in unoptimized 
poor yields. Compound 2m was synthesized by reacting previously 
described 1-(p-cyanophenyl) pyrazole 6a with methylmagnesium 
bromide in reducing conditions. Finally, compound 2n was 
prepared from 4-(p-fluorophenyl)-3,5-dimethyl pyrazole 10a 
which was N-arylated with p-cyanomethyl phenyl bromide, 
according to Buchwald-Hartwig reaction experimental protocol26 
(microwave reaction, aquous K2CO3 and DMSO, CuI and L-
proline, 140°C, 26 h). The resulting pyrazole intermediate 13 was 
then reduced with sodium borohydride in the presence of cobalt (II) 
chloride, to obtain the corresponding target benzylamine 2n.
Scheme 4. Variations on the benzylamine: compounds 2l-na 
N N
F
H2N
N NNC
F
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N
F
13 2n
10a
10a
12
a b
6a 2m
N N
F
H2NNC
N N
F
c
ed
2l
CN
N
N
F
H2N
aReagents and conditions: (a) 3-cyanophenylboronic acid, 
Cu(OAc)2.H2O, pyridine, DMF, 125°C, 3h, 11%; (b) LiAlH4, THF, 
r.t, 3h, 31%; (c) MeMgBr, THF, r.t, 5h, then LiAlH4, THF, 0° to 
r.t, 13% (two steps); (d) 4-bromobenzyl cyanide, CuI, L-proline, 
K2CO3, DMSO, 140°C, 26h, 33%; (e) NaBH4, CoCl2, MeOH, r.t, 
1h, 25%.
Compounds 2l, 2m and 2n mostly maintained the activity of the 
early pyrazole lead 2a, and showed high ASIC2a isoform-
selectivity (Table 2), whereas the nitrile intermediates 6a was 
inactive, pointing out the relevance of the presence of the primary 
amine function.
The “blue” exploration was expanded by constraining the amine 
function within a 5-membered ring. To this aim, compounds 2o-r 
bearing a more symmetrical (2o, 2q) or unsymmetrical amine (2p, 
2r) and a p-F (2o, 2p) or m-F substituent at the 4-phenyl ring (2q, 
2r) were prepared. The synthesis of this sub-series of compounds 
is reported in Scheme 5. Namely, previously described 4-(p-
fluorophenyl)-3,5-dimethyl pyrazole intermediate 10a, and 4-(m-
fluorophenyl)-3,5-dimethyl pyrazole intermediate 10b (prepared as 
10a in Scheme 3, using m-fluorophenyl boronic acid) were N-
arylated with N-Boc-5-bromo isoindoline, using CuI in basic 
conditions in a microwave reactor. 
The resulting N-Boc-protected 4-(p-fluorophenyl) pyrazoles 14a 
and 15a were obtained in 42% and 15% unoptimized yield, 
respectively. Then, removal of the N-Boc protecting group in acidic 
conditions afforded the corresponding target compounds 2o and 2q 
in 32% and 63% yields, respectively. Intermediates 10a and 10b 
underwent the same coupling reaction with 6-bromo indoline, 
obtaining the corresponding target compounds 2p and 2r in 44% 
and 13% yield, respectively (Scheme 5). 
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Scheme 5. Rigidification of the benzylamine: compounds 2o-ra
aReagents and conditions: (a) N-Boc-5-bromo isoindoline, CuI, 
aqueous K2CO3, L-proline, DMSO, microwave, 75°C, 4 h then 
140°C, 13 h, 42% (14a) or 15% (15a); (b) 4N HCl in dioxane, 
30min, r.t., 32% (2o) or 63% (2q); (a’) 6-bromo indoline, aqueous 
K2CO3, CuI, L-proline, DMSO, microwave, 140°C, 6 h, 44% (2p) 
or 13% (2r).
Table 2. Compounds 2k-w and 6a: ASIC inhibitiona
Entry ASIC1aa ASIC2aa ASIC1a/2aa
2a >30 18.9 ± 6.9 10.9 ± 1.6
2j >30 >30 >30
2k >30 16.8 ± 5.4 >30
2l >30 15.6 ± 2.9 >30
2m >30 8.7 ± 2.3 >30
2n >30 11.7 ± 2.7 >30
2o >30 8.2 ± 1.5 >30
2p >30 >30 >30
2q >30 9.9 ± 1.1 11.3 ± 1.0
2r >30 >30 >30
2s >30 6.1 ± 1.1 8.5 ± 1.8
2t >30 >30 >30
2u >30 17.0 ± 4.7 >30
2v >30 >30 >30
2w >30 >30 >30
6a >30 >30 >30
a IC50 were determined as described in the Supplementary 
Information; they are expressed in M and are the average value of 
at least n=3 independent experiments ± SEM. 
The inhibition of ASICs constructs by “blue” compounds 2o-r is 
reported in Table 2. In particular, the isoindole derivative 2o 
exhibited good in vitro activity and complete ASIC2a isoform-
selectivity. Conversely, compound 2q inhibited both ASIC2a and 
ASIC1a/2a isoforms (IC50 = 9.9 M and 11.3 M, respectively). 
Notably, the corresponding indoline derivatives 2p and 2r were 
inactive. 
Finally, the phenyl ring bearing the benzyl amine function was 
replaced (“green” exploration”) by a 2-pyridine (2s) and a 3-
pyridine (2t) moiety, whereas dihydropyrrolo[3,4-d]pyrimidine 
homologues 2u and 2v and the N-Me derivative of the latter 
compound 2w were prepared. Their synthesis is depicted in 
Scheme 6.
Scheme 6. Phenyl substitution: compounds 2s-wa 
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F F
aReagents and conditions: (a) 60% NaH, DMF, 0°C, 30 min then 6-
fluoronicotinonitrile, r.t, 1h (98%, 16) or tert-butyl 4-chloro-5,7-
dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxylate, r.t., 1 h (9%, 
18); (b) 5-bromo-2-cyanopyridine, Cs2CO3, CuI, 1,2-
cyclohexanediamine, microwave, 120°C, 13h, 19%; (c) LiAlH4, 
THF, r.t, 1h, 4% (2s), 16% (2t); (d) 4N HCl in dioxane, r.t, 1-3h, 
8% (2u), 19% (2v); (e) 2/1 THF/DMF, DIPEA, microwave, 150°, 
14h, 58%; (f) H2, TEA, MeOH, 10% Pd/C, 45°C, 1 h; (g) 
formaldehyde, NaCNBH3, MeOH, r.t, 1 h, 57%.
Previously described 4-(p-fluorophenyl)-3,5-dimethyl pyrazole 
intermediate 10a was smoothly N-arylated with p-cyano-2-pyridyl 
fluoride in basic conditions (NaH in DMF); the resulting 1-(p-
cyano-2-pyridyl) pyrazole 16 was reduced to the corresponding 
benzylamine derivative 2s with lithium aluminium hydride in 
unoptimized, poor yields. Instead, the corresponding m-F analogue 
2t was synthesized from 10a and 5-bromo-2-cyanopyridine using 
Cs2CO3, CuI and 1,2-cyclohexanediamine. This coupling reaction 
was run in a microwave reactor for 13 h at 120°C, and afforded 
cyano intermediate 17, which was then reduced to amine 2t in a 
poor, unoptimized 16% yield. Alternatively, compound 10a was N-
arylated with tert-butyl 4-chloro-5,7-dihydro-6H-pyrrolo[3,4-
d]pyrimidine-6-carboxylate as seen earlier; the resulting N-Boc-
protected pyrazole 18 was deprotected in acid conditions to yield 
the target compound 2u in poor, unoptimized yields. Then, 
N
N
F
Y
X
14a
N
N
F
Y
X
BrY
X
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b
X=CH2
Y=NH
2o, X=NH, Y=CH2
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intermediate 10b was transformed into the target compound 2v by 
N-arylation followed by removal of the Cl atom by hydrogenolysis 
to give intermediate 20, which was finally deprotected in acid 
conditions to the corresponding NH-free pyrazole 2v. Finally, this 
compound was N-methylated to yield compound 2w in good yields 
(Scheme 6).
As shown in Table 2, none of the compounds 2s-w inhibited  
ASIC1a. The presence of a 2-pyridyl ring was well tolerated by 
ASIC2a (2s). Conversely, the presence of a 3-pyridyl ring led to 
complete inactivity (2t). The dihydropyrrolo[3,4-d]pyrimidine 
derivative 2u was an ASIC2 inhibitor (IC50 = 17.0 M) selective 
against the ASIC1a/2a heterodimer. Surprisingly, its close 
congeners 2v and 2w, bearing a 4-(m-fluorophenyl) substitution, 
resulted to be completely inactive. 
Compound 2a, 2o and 2u were profiled in terms of early 
physicochemical and ADME properties. As to in vivo PK in mice 
priority was given to the characterization of 2u over 2o owing to its 
more drug-like physicochemical features (cLogP = 2.6 and 4.1; 
TPSA = 56 and 29 Å2, for 2u and 2o, respectively). The summary 
of both the in vitro and in vivo characterization studies performed 
is reported in Table 3.
Table 3. ADME profiling: compounds 2a, 2o and 2u
Compound/Assay 2a 2u 2o
cLogP a 3.9 2.6 4.2
TPSA (Å2) a 44 56 30
Solubility (g/ml)b 73 32 56
PPB (%)c 93 94 95
h-ERG (IC50, M) >30 >30 >30
CYP450 (IC50, 
M)d
0.4 [1A2] 0.8 [1A2] 0.2 [1A2]
4.8 [2D6]
Cl (ml/min/Kg)e 224 34 NT
Vd (l/Kg) 50.9 1.4 NT
Cmax (M) 0.09 2.6 NT
F (%) 60 100 NT
B/P ratio f 61 1.3 NT
a calculated logP and topological polar surface area; b kinetic 
solubility at pH 7.4; c % of bound compound to human serum 
albumin measured by NMR-based analysis; d only CYP450 
isoforms showing IC50 <10 M are reported; e in vivo PK studies 
were performed at 1 mg/Kg, i.v. and at 3 mg/Kg, p.o.; f brain 
penetration studies were performed at 1 mg/Kg, i.v. and B/P was 
calculated from 2h to 8h after dosing. 
As to physicochemical descriptors, compound 2u was significantly 
less lipophilic than 2a and exhibited a greater TPSA value. Both 
compounds showed acceptable kinetic solubility and plasma 
protein binding (PPB). No inhibition of hERG was observed up to 
30M concentration. In terms of inhibition of CYP450 isoforms, 
compound 2a was found to inhibit two different isoforms, i.e. 1A2 
and 2D6, although at different extents, whereas 2u inhibited only 
the 1A2 isoform. Particularly relevant were the differences 
observed in the in vivo pharmacokinetics in mice. Both compounds 
were tested at 1 mg/kg, i.v. and at 3 mg/Kg, p.o. Notably, 2a was 
highly cleared following i.v. administration (Cl = 224 ml/min/Kg), 
but widely distributed in tissues (Vd = 50.9 l/Kg), resulting in a low 
Cmax after oral administration (Cmax =0.09 M). However, being 
highly brain penetrant (B/P = 61), a relevant  total brain 
concentration was observed after the administration of 1 mg/Kg 
dose, i.v. (Cmax =2.46 M). Conversely, compound 2u showed a 
more balanced pharmacokinetic profile, owing to a sizable 
enhancement of the metabolic stability (Cl = 34 ml/min/Kg) with 
respect to compound 2a, an appropriate tissue distribution (Vd=1.4 
l/Kg), complete absorption after oral administration (F=100%) 
along with a significantly higher exposure p.o. with respect to 2a 
(Cmax = 2.6 M), and good brain penetration (B/P = 1.3). The 
relevant improvement of pharmacokinetic profile of 2u vs 2a was 
most likely due to the lack of the basic, metabolically labile primary 
benzylamine function present in compound 2a, which was 
appropriately masked in 2u within the constrained 
dihydropyrrolo[3,4-d]pyrimidine bicyclic moiety.
In conclusion, the described exploratory strategy enabled the 
identification of novel ASIC2 inhibitors. In particular, the “cyano” 
optimization approach, focused on the stabilization of the terminal 
benzylamine function, allowed to obtain compounds 20 and 2u as 
selective ASIC2a the in vivo-compliant lead compound 2u. This 
compound, owing to its relevant drug-like character and balanced 
pharmacokinetic profile (including brain penetration), may 
represent a valuable tool compound to validate p.o. the role of 
ASIC2 in vivo in animal models of different type of CNS 
pathologies. In addition, 2u can be seen as a foundation molecule 
for future optimization studies.
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